Selegiline is a monamine-oxidase inhibitor used primarily for treatment of canine cognitive dysfunction syndrome (CDS) . Therapeutic effects of selegiline are thought to result in part from enhanced catecholaminergic nerve function and increased dopamine levels in the CNS.
Available in 2, 5, 10, 15, and 30 mg tablets.
Recommended dose in dogs is 1 mg/kg (0.45 mg/lb), administered in the morning. During the first two months of therapy, the patient should be re-evaluated regularly for clinical response by history and physical examination.
The dose can be increased to a maximum of 2 mg/kg once daily after the initial one month trial, or discontinued if poor response is observed.
- Mills D & Ledger R (2001) The effects of oral selegiline hydrochloride on learning and training in the dog: a psychobiological interpretation. Prog Neuropsychopharmacol Biol Psychiatry 25(8):1597-1613
- Knoll J et al (1996) (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-) PPAP], act primarily as potent stimulants of action potential - transmitter release coupling in the catecholaminergic neurons. Life Sci 58:817-827
- Braddock JA et al (2004) Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism. Aust Vet J 82(5):272-277